RxDoctor Payments Data

Joseph Deluca, MD

Internal Medicine · El Dorado, ARNPI 1417969478

Payments from drug & device makers

$180in general payments, 2019–2025

Across 11 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$48
  • AstraZeneca$43
  • Novo Nordisk$30
  • Novartis$28
  • Boston Scientific$20
  • Merck$11

What the payments were for

  • Food & beverage$16994%
  • Education$126%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer3$48
AstraZeneca3$43
Novo Nordisk2$30
Novartis1$28
Boston Scientific1$20
Merck1$11

How this compares

$180 in reported general payments places this provider in the 45th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$129,104
Medicare patients
560
Services billed
1,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide175$208,300
EliquisApixaban191$138,312
FarxigaDapagliflozin Propanediol86$76,674
Tresiba Flextouch U-200Insulin Degludec66$72,811
JanuviaSitagliptin Phosphate80$71,954
Trelegy ElliptaFluticasone/Umeclidin/Vilanter111$70,493
RybelsusSemaglutide35$66,637
LinzessLinaclotide78$60,096
JardianceEmpagliflozin81$57,524
XareltoRivaroxaban67$52,330
MounjaroTirzepatide35$41,737
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen825$25,593
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$25,144
Tresiba Flextouch U-100Insulin Degludec47$25,008
EntrestoSacubitril/Valsartan24$21,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$30$274,937210 claims
PfizerEliquis$48$138,312191 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$43$117,760168 claims
MerckJanuvia$11$71,95480 claims
NovartisEntresto$28$21,45824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in El Dorado

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →